No association of low-dose aspirin with severe COVID-19 in France: A cohort of 31.1 million people without cardiovascular disease

Article Medicine, General & Internal

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby et al.

Summary: In patients hospitalized with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.

LANCET (2022)

Add to Collection

Article Medicine, General & Internal

Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19

Jonathan H. Chow et al.

Summary: This study investigates the association between early aspirin use and in-hospital mortality in patients with moderate COVID-19. The results suggest that early aspirin use is associated with lower odds of 28-day in-hospital mortality and a reduced risk of pulmonary embolism. However, the risk of deep vein thrombosis was not significantly decreased. These findings highlight the potential benefits of aspirin in the treatment of high-risk COVID-19 patients.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Anesthesiology

Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019

Jonathan H. Chow et al.

Summary: A retrospective cohort study in multiple hospitals in the United States showed that aspirin use in COVID-19 patients may be associated with reduced risk of mechanical ventilation, ICU admission, and in-hospital mortality. Further studies are needed to confirm a causal relationship.

ANESTHESIA AND ANALGESIA (2021)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19

Husam M. Salah et al.

AMERICAN JOURNAL OF CARDIOLOGY (2021)

Add to Collection

Article Peripheral Vascular Disease

Antihypertensive Drugs and COVID-19 Risk A Cohort Study of 2 Million Hypertensive Patients

Laura Semenzato et al.

Summary: Recent evidence suggests that hypertensive patients treated with ACE inhibitors or ARBs may have a lower risk of COVID-19 hospitalization and intubation/death compared to those treated with CCBs. This contradicts initial hypotheses regarding the association between renin-angiotensin-aldosterone system inhibitors and COVID-19 risk, raising new questions for further research.

HYPERTENSION (2021)

Add to Collection

Article Pharmacology & Pharmacy

Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19

Jessica M. Franklin et al.

Summary: The emergence of the SARS-CoV-2 virus has led to an urgent need for evidence on medical interventions and outcomes of COVID-19. While many RCTs are in progress, there is growing interest in using nonrandomized real-world evidence to supplement RCT evidence. However, concerns about nonrandomized RWE studies on medications and COVID-19 outcomes with varying conclusions have been highlighted.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection

Eugene Merzon et al.

Summary: The study observed a negative association between the use of aspirin and COVID-19 infection, disease duration, and mortality. Aspirin users were typically older, had lower BMI, and higher rates of conditions like hypertension and diabetes compared to non-users.

FEBS JOURNAL (2021)

Add to Collection

Article Multidisciplinary Sciences

Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration

Thomas F. Osborne et al.

Summary: The study found that pre-diagnosis aspirin prescription was significantly associated with decreased mortality rates for COVID-19 positive Veterans, indicating the potential benefits of aspirin for patients with COVID-19.

PLOS ONE (2021)

Add to Collection

Article Emergency Medicine

Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis

Yushu Wang et al.

Summary: This study found that the use of antiplatelet agents does not have a significant impact on the risk of severe COVID-19 disease or mortality. However, the benefit and risk of using these agents should be fully considered, especially in the presence of thrombocytopenia in COVID-19 patients.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal